MeSH D003699 - hepatitis d
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Roche | Ribavirin, Peginterferon alfa-2a | Pegasys Copegus | 2004-06-04 | |||
| Interferon alfa-2a | Roferon-A | 1986-06-04 | ||||
| Merck & Co | Interferon alfa-2b | Intron A | 1986-06-04 | |||
| Interferon alfa-2b | IntronA | 2000-03-09 | ||||
| Peginterferon alfa-2b | PegIntron | 2001-01-19 | ||||
| Ribavirin, Peginterferon alfa-2b | PegIntron/ Rebetol Combo Pack | 2008-06-13 | ||||
| Interferon alfa-2b | Viraferon | 2000-03-09 | ||||
| Peginterferon alfa-2b | ViraferonPeg | 2000-05-28 | ||||
| Horizon Therapeutics Public | Interferon gamma-1b | Actimmune | 1999-02-25 | $122.816 M | Q3/22-Q2/23 | |
| Pharma& | Peginterferon alfa-2a | Pegasys | 2002-10-16 |
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
0%0/7
Phase 3
100%4/4
Approved: 4Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use